ATLEWArtelo Biosciences, Inc.

About Artelo Biosciences, Inc. (ATLEW)

Artelo Biosciences, Inc. (ATLEW) is a N/A company headquartered in Solana Beach, CA, United States whose shares trade over-the-counter on the Pink tier.

Artelo Biosciences, Inc. is a San Diego-based clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate the endocannabinoid system (the "ECS"), including a solid-state composition of cannabidiol ("CBD cocrystal"), with improved pharmaceutical-like properties which could have a meaningful impact on cannabinoid-based drug development. Artelo's management team is highly experienced and has a successful history of development, regulatory approval and commercialization of pharmaceuticals. Artelo's pipeline broadly leverages leading scientific methodologies to ECS modulation, balances risk across mechanism of action and stages of development, and represents a comprehensive approach in utilizing the power of the ECS to develop pharmaceuticals for patients with unmet healthcare needs. In addition to Artelo's cocrystal program, the Company is currently evaluating ART27.13, which is entering a Phase 1b/2a trial for cancer related anorexia, and ART26.12, which is being studied as an endocannabinoid modulator and cancer therapeutic and is in the late pre-clinical stage.

ATLEW key facts

Ticker symbol

ATLEW

Market tier

Pink

Headquarters

Solana Beach, CA, United States

Country of incorporation

US

Year of incorporation

2011

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Artelo Biosciences, Inc. leadership

• Gregory Gorgas — President, CEO, CFO
• Peter O'Brien — Senior VP

Explore more: Pink stocks · OTC stocks starting with A